Better Together: B7S1 Checkpoint Blockade Synergizes with anti-PD1

Melissa A. Meyer; David G. DeNardo

doi:10.1016/j.immuni.2018.03.029

Better Together: B7S1 Checkpoint Blockade Synergizes with anti-PD1

Melissa A. Meyer, David G. DeNardo

Research output: Contribution to journal › Short survey › peer-review

3 Scopus citations

Abstract

T cell checkpoint blockades can produce durable clinical responses, but only some patients and cancer types respond. In this issue of Immunity, Li et al. (2018) show B7S1-B7S1R signaling additionally regulates CD8⁺ T cell responses by working with the PD1-PDL1 checkpoint to block anti-tumor immunity. T cell checkpoint blockades can produce durable clinical responses, but only some patients and cancer types respond. In this issue of Immunity, Li et al. (2018) show B7S1-B7S1R signaling additionally regulates CD8⁺ T cell responses by working with the PD1-PDL1 checkpoint to block anti-tumor immunity.

Original language	English
Pages (from-to)	621-623
Number of pages	3
Journal	Immunity
Volume	48
Issue number	4
DOIs	https://doi.org/10.1016/j.immuni.2018.03.029
State	Published - Apr 17 2018

Access to Document

10.1016/j.immuni.2018.03.029

Cite this

@article{a9f76f274eac414f879b2b0d9d9f7bfc,

title = "Better Together: B7S1 Checkpoint Blockade Synergizes with anti-PD1",

abstract = "T cell checkpoint blockades can produce durable clinical responses, but only some patients and cancer types respond. In this issue of Immunity, Li et al. (2018) show B7S1-B7S1R signaling additionally regulates CD8+ T cell responses by working with the PD1-PDL1 checkpoint to block anti-tumor immunity. T cell checkpoint blockades can produce durable clinical responses, but only some patients and cancer types respond. In this issue of Immunity, Li et al. (2018) show B7S1-B7S1R signaling additionally regulates CD8+ T cell responses by working with the PD1-PDL1 checkpoint to block anti-tumor immunity.",

author = "Meyer, {Melissa A.} and DeNardo, {David G.}",

note = "Publisher Copyright: {\textcopyright} 2018",

year = "2018",

month = apr,

day = "17",

doi = "10.1016/j.immuni.2018.03.029",

language = "English",

volume = "48",

pages = "621--623",

journal = "Immunity",

issn = "1074-7613",

number = "4",

}

TY - JOUR

T1 - Better Together

T2 - B7S1 Checkpoint Blockade Synergizes with anti-PD1

AU - Meyer, Melissa A.

AU - DeNardo, David G.

PY - 2018/4/17

Y1 - 2018/4/17

N2 - T cell checkpoint blockades can produce durable clinical responses, but only some patients and cancer types respond. In this issue of Immunity, Li et al. (2018) show B7S1-B7S1R signaling additionally regulates CD8+ T cell responses by working with the PD1-PDL1 checkpoint to block anti-tumor immunity. T cell checkpoint blockades can produce durable clinical responses, but only some patients and cancer types respond. In this issue of Immunity, Li et al. (2018) show B7S1-B7S1R signaling additionally regulates CD8+ T cell responses by working with the PD1-PDL1 checkpoint to block anti-tumor immunity.

AB - T cell checkpoint blockades can produce durable clinical responses, but only some patients and cancer types respond. In this issue of Immunity, Li et al. (2018) show B7S1-B7S1R signaling additionally regulates CD8+ T cell responses by working with the PD1-PDL1 checkpoint to block anti-tumor immunity. T cell checkpoint blockades can produce durable clinical responses, but only some patients and cancer types respond. In this issue of Immunity, Li et al. (2018) show B7S1-B7S1R signaling additionally regulates CD8+ T cell responses by working with the PD1-PDL1 checkpoint to block anti-tumor immunity.

UR - http://www.scopus.com/inward/record.url?scp=85045083150&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2018.03.029

DO - 10.1016/j.immuni.2018.03.029

M3 - Short survey

C2 - 29669244

AN - SCOPUS:85045083150

SN - 1074-7613

VL - 48

SP - 621

EP - 623

JO - Immunity

JF - Immunity

IS - 4

ER -

Better Together: B7S1 Checkpoint Blockade Synergizes with anti-PD1

Abstract

Access to Document

Other files and links

Fingerprint

Cite this